Evidence map›Paper›PMID 33081531›Full record

Trial reportCirculation2021

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.

Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart J Pocock, Peter Carson, Inder Anand, Wolfram Doehner, Markus Haass and 9 more

Erratum issued Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It reports registered trial NCT03057977. Cited by 196 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
196citing papers in PubMed, 15 pooled it
34.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03057977 phase3completed

A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Ran2017Enrolled3,730Registered outcomes10Posted comparisons10ConditionsHeart FailureArmsempagliflozin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

196 citing papers in PubMed, 15 syntheses or guidelines pooled it, 414 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

136 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 16 institutions in 8 countries.

Milton PackerBaylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.).
Stefan D AnkerDepartment of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany (S.D.A., W.D.).
Javed ButlerDepartment of Medicine, University of Mississippi School of Medicine, Jackson (J.B.).
Gerasimos FilippatosNational and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Greece (G.F.).
João Pedro FerreiraUniversité de Lorraine, Inserm INI-CRCT, CHRU, Nancy, France (J.P.F., F.Z.).
Stuart J PocockDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, UK (S.J.P.).
Peter CarsonWashington DC Veterans Affairs Medical Center (P.C.).
Inder AnandDepartment of Cardiology, University of Minnesota, Minneapolis (I.A.).
Wolfram DoehnerDepartment of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany (S.D.A., W.D.).
Markus HaassTheresienkrankenhaus and St.Hedwig-Klinik, Mannheim, Germany (M.H.).
Michel KomajdaDepartment of Cardiology, Hospital Saint Joseph, Paris, France (M.K.).
Alan MillerUniversity of Florida, Jacksonville (A.M.).
Steen PehrsonDepartment of Cardiology, University Hospital, Rigshospitalet, Copenhagen, Denmark (S.P.).
John R TeerlinkSection of Cardiology, San Francisco Veterans Affairs Medical Center, CA (J.R.T.).
Martina BrueckmannSchool of Medicine, University of California, San Diego (J.R.T.).
Waheed JamalBoehringer Ingelheim International GmbH, Ingelheim, Germany (M.B., W.J., C.Z.).
Cordula ZellerBoehringer Ingelheim International GmbH, Ingelheim, Germany (M.B., W.J., C.Z.).
Sven SchnaidtBiostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (D.M., S.S.).
Faiez ZannadUniversité de Lorraine, Inserm INI-CRCT, CHRU, Nancy, France (J.P.F., F.Z.).
Boehringer Ingelheim (Germany) · DEInserm · FRBaylor College of Medicine · USBerlin-Brandenburger Centrum für Regenerative Therapien · DECopenhagen University Hospital · DKGerman Centre for Cardiovascular Research · DEHôpital Paris Saint-Joseph · FRNational and Kapodistrian University of Athens · GRSan Francisco VA Medical Center · USSt. Hedwig-Krankenhaus · DEUniversity of Florida · USUniversity of London · GBUniversity of Minnesota · USUniversity of Mississippi Medical Center · USUniversity of San Diego · USVeterans Health Administration · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmpagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, with or without diabetes, but additional data are needed about the effect of the drug on inpatient and outpatient events that reflect worsening heart failure.

methodsWe randomly assigned 3730 patients with class II to IV heart failure with an ejection fraction of ≤40% to double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to recommended treatments for heart failure, for a median of 16 months. We prospectively collected information on inpatient and outpatient events reflecting worsening heart failure and prespecified their analysis in individual and composite end points.

resultsEmpagliflozin reduced the combined risk of death, hospitalization for heart failure or an emergent/urgent heart failure visit requiring intravenous treatment (415 versus 519 patients; empagliflozin versus placebo, respectively; hazard ratio [HR], 0.76; 95% CI, 0.67-0.87;

conclusionsIn patients with heart failure and a reduced ejection fraction, empagliflozin reduced the risk and total number of inpatient and outpatient worsening heart failure events, with benefits seen early after initiation of treatment and sustained for the duration of double-blind therapy. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.

Indexed as

Benzhydryl CompoundsGlucosidesHeart FailureHumansSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorsempagliflozinheart failuresodium-glucose transporter 2 inhibitors

Identifiers

PMID33081531
PMCPMC7834905
OpenAlexW3093992036

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.